Your drug development solution provider

model-informed-pediatric-development-applied-to-bilastine-ontogenic-pk-model-development-dose-selection-for-first-time-in-children-and-pk-study-design

7 noviembre, 2017

Be the first to know about our initiatives, news and other related information

RESPONSIBLE: DYNAKIN S.L. PURPOSE: Respond to your information request. RIGHTS: You have the right to access, rectify and delete the data, as well as other rights, as explained in the additional information. ADDITIONAL INFORMATION:You can consult the additional and detailed information on Data Protection here.

I accept the terms of use.

Be the first to know about our initiatives, news and other related information

RESPONSIBLE: DYNAKIN S.L. PURPOSE: Respond to your information request. RIGHTS: You have the right to access, rectify and delete the data, as well as other rights, as explained in the additional information. ADDITIONAL INFORMATION:You can consult the additional and detailed information on Data Protection here.

I accept the terms of use.

Categories

  • No hay categorías
Contact us

We wish to know from you,
we wish to help you.

RESPONSIBLE: DYNAKIN S.L. PURPOSE: Respond to your information request. RIGHTS: You have the right to access, rectify and delete the data, as well as other rights, as explained in the additional information. ADDITIONAL INFORMATION:You can consult the additional and detailed information on Data Protection here.

I accept the terms of use.

↑